Log in

NASDAQ:LQDA - Liquidia Technologies Stock Price, Forecast & News

-0.08 (-1.56 %)
(As of 02/17/2020 06:00 AM ET)
Today's Range
Now: $5.04
50-Day Range
MA: $5.50
52-Week Range
Now: $5.04
Volume42,774 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Liquidia Technologies, Inc, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension. The company is also developing LIQ865, which completed Phase 1 clinical trials for the treatment of local post-operative pain. Read More…

Industry, Sector and Symbol

Industry N/A
Current SymbolNASDAQ:LQDA



Sales & Book Value

Annual SalesN/A



Next Earnings Date2/25/2020 (Estimated)
OptionableNot Optionable

Receive LQDA News and Ratings via Email

Sign-up to receive the latest news and ratings for LQDA and its competitors with MarketBeat's FREE daily newsletter.

Liquidia Technologies (NASDAQ:LQDA) Frequently Asked Questions

What is Liquidia Technologies' stock symbol?

Liquidia Technologies trades on the NASDAQ under the ticker symbol "LQDA."

How were Liquidia Technologies' earnings last quarter?

Liquidia Technologies Inc (NASDAQ:LQDA) posted its quarterly earnings data on Wednesday, November, 13th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.52) by $0.20. View Liquidia Technologies' Earnings History.

When is Liquidia Technologies' next earnings date?

Liquidia Technologies is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Liquidia Technologies.

What price target have analysts set for LQDA?

1 brokers have issued 1 year price targets for Liquidia Technologies' stock. Their forecasts range from $37.00 to $37.00. On average, they expect Liquidia Technologies' share price to reach $37.00 in the next year. This suggests a possible upside of 634.1% from the stock's current price. View Analyst Price Targets for Liquidia Technologies.

What is the consensus analysts' recommendation for Liquidia Technologies?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Liquidia Technologies in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Liquidia Technologies.

What are Wall Street analysts saying about Liquidia Technologies stock?

Here are some recent quotes from research analysts about Liquidia Technologies stock:
  • 1. According to Zacks Investment Research, "Liquidia Technologies, Inc. is a late-stage clinical biopharmaceutical company. It focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. The company's product candidate consists of LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain which are in clinical stage. Liquidia Technologies, Inc. is based in NC, United States. " (1/15/2020)
  • 2. Wedbush analysts commented, "We base our $27 price target on a sum-of-the-parts analysis derived from: (1) the P/E value of La Jolla’s current commercial business (Giapreza); (2) an NPV of its pipeline (LJPC-401); and (3) our estimated year-end 2019 fully diluted net cash of $2.03/share to arrive at our price target. We value the current commercial business at $12.94 per share and the pipeline at $11.99 per share. The commercial business value is based on a P/E multiple assumption of 30x our 2024E EPS of $0.75, discounted at 15%." (6/28/2019)

Has Liquidia Technologies been receiving favorable news coverage?

Media headlines about LQDA stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Liquidia Technologies earned a daily sentiment score of 1.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Liquidia Technologies.

Are investors shorting Liquidia Technologies?

Liquidia Technologies saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 234,100 shares, a decrease of 5.1% from the January 15th total of 246,800 shares. Based on an average daily trading volume, of 182,600 shares, the days-to-cover ratio is currently 1.3 days. Approximately 12.3% of the shares of the stock are sold short. View Liquidia Technologies' Current Options Chain.

What other stocks do shareholders of Liquidia Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Liquidia Technologies investors own include vTv Therapeutics (VTVT), Agile Therapeutics (AGRX), Nabriva Therapeutics (NBRV), Vaxart (VXRT), Aduro BioTech (ADRO), Crispr Therapeutics (CRSP), Inovio Pharmaceuticals (INO), TrovaGene (TROV), Zynerba Pharmaceuticals (ZYNE) and Amarin (AMRN).

Who are Liquidia Technologies' key executives?

Liquidia Technologies' management team includes the folowing people:
  • Mr. Neal F. Fowler, CEO & Director (Age 57)
  • Mr. Robert A. Lippe, Chief Operations Officer (Age 54)
  • Mr. William R. Kenan Jr., Co-Founder
  • Dr. Ginger Denison, Co-Founder
  • Mr. Timothy M. Albury, Interim Chief Financial Officer (Age 50)

When did Liquidia Technologies IPO?

(LQDA) raised $50 million in an initial public offering (IPO) on Thursday, July 26th 2018. The company issued 4,500,000 shares at $10.00-$12.00 per share. Jefferies and Cowen acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

Who are Liquidia Technologies' major shareholders?

Liquidia Technologies' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Canaan Partners VIII LLC (15.63%), ArrowMark Colorado Holdings LLC (5.87%), Keel Point LLC (1.09%), State Street Corp (0.99%), Jacobs Levy Equity Management Inc. (0.25%) and Renaissance Technologies LLC (0.10%). Company insiders that own Liquidia Technologies stock include Arthur S Kirsch, Benjamin Maynor, Kevin K Gordon, Plc Glaxosmithkline, Timothy Albury and Viii Lp Canaan. View Institutional Ownership Trends for Liquidia Technologies.

Which major investors are selling Liquidia Technologies stock?

LQDA stock was sold by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP, Renaissance Technologies LLC and Alambic Investment Management L.P.. Company insiders that have sold Liquidia Technologies company stock in the last year include Benjamin Maynor, Kevin K Gordon and Timothy Albury. View Insider Buying and Selling for Liquidia Technologies.

Which major investors are buying Liquidia Technologies stock?

LQDA stock was bought by a variety of institutional investors in the last quarter, including Canaan Partners VIII LLC, Keel Point LLC, Jacobs Levy Equity Management Inc., ArrowMark Colorado Holdings LLC, Wedbush Securities Inc., State Street Corp, UBS Group AG and Barclays PLC. Company insiders that have bought Liquidia Technologies stock in the last two years include Arthur S Kirsch, Plc Glaxosmithkline and Viii Lp Canaan. View Insider Buying and Selling for Liquidia Technologies.

How do I buy shares of Liquidia Technologies?

Shares of LQDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Liquidia Technologies' stock price today?

One share of LQDA stock can currently be purchased for approximately $5.04.

MarketBeat Community Rating for Liquidia Technologies (NASDAQ LQDA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  115 (Vote Outperform)
Underperform Votes:  129 (Vote Underperform)
Total Votes:  244
MarketBeat's community ratings are surveys of what our community members think about Liquidia Technologies and other stocks. Vote "Outperform" if you believe LQDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LQDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Featured Article: Risk Tolerance

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel